FB Pixel no scriptBiotechnology | KrASIA
MENU
KrASIA

Biotechnology

Insights

AI-driven drugmakers fuel wave of cross-border deals in China

Investors are reassessing de novo drug design as firms close major BD transactions.

5 mins read
  • Chair Zhao Yan is steering the company away from hype-driven marketing, investing in synthetic biology to rebuild growth and credibility.

    Features

    After years of “sleep,” Bloomage faces biotech’s hard realities with a bet on science

    9 mins read

Most Recent

See All